The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...
GlobalData on MSN9h
MindMed doses first subject in Phase III Panorama study of GAD tabletMind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of lysergide ...
Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Mind Medicine (MNMD – Research Report). The associated price ...
The Axsome management team will provide an overview of SYMBRAVO and anticipated commercial plans. The presenters will be available to answer questions at the end of the presentation. To access the ...
Selvaraju highlighted Axsome earlier in the week as a Top Pick within their coverage universe, reiterating the Buy rating and emphasizing the company's strengthened position following the FDA's green ...
BuzzFeed on MSN19h
After The Fall Of Roe V Wade, We Asked Men If They'd Be Willing To Take Male Birth Control And Here's What They SaidFollowing the Supreme Court’s overturning Roe v. Wade, conversations about male hormonal birth control have never been more vital. As it is, the options for men wanting to prevent pregnancy are scant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback